# US 2021/0171598 A1 · Peptide hormone with one or more o-glycans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171598 A1
- Document ID: US20210171598A1
- Status: Published application
- Kind: A1
- Application number: 16/768,584
- Filed: 2018-11-30
- Published: 2021-06-10
- Earliest claimed: 2017-12-01
- Assignees: University of Copenhagen
- Applicants: University of Copenhagen
- Inventors: Katrine TER-BORCH GRAM SCHJOLDAGER; Henrik CLAUSEN; Sergey Y. VAKRUSHEV; Christoffer Knak GOTH; Thomas Daugbjerg MADSEN; Lasse H. HANSEN; Jens P. GØTZE
- Web page: https://patentgrep.com/patent/US20210171598A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 1/006: {of peptides containing derivatised side chain amino acids}
- C07K 1/1072: {by covalent attachment of residues or functional groups}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/2207: {Gastrins; Cholecystokinins [CCK]}
- A61K 38/2271: {Neuropeptide Y}
- A61K 38/23: Calcitonins
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 38/31: Somatostatins
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a peptide hormone with one or more O-glycans attached at specific amino acid residues as well as to formulations comprising the same.

## Claims

### Claim 1

A formulation comprising at least one molecule of a peptide hormone species exhibiting a specific glycosylation pattern of one or more O-linked glycan(s) at a predetermined specific site of said peptide hormone species, wherein specific, defined glycosylation pattern means that the each molecule of said peptide hormone in said pharmaceutical formulation displays structural homogeneity with respect to the site of glycan attachment and/or with respect to the glycan attachment.

### Claim 2 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said peptide hormone species is selected from the group of sequences comprising SEQ ID NOs: 1, 2, 3, 5, 6, 7, 14, 15, 16, 21, 22, 23, 24, 25, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 51, 52, 54, 55, 56, 57, 72, 73, 74, 76, 79, 8, 81, 83, 84, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 106, 107, 108, 109, 113, 116, 117, 118, 119, 120, 130, 131, 135, 136, 143, 144, 147, 163, 164, 167, 168, 170, 184, 185, 186, 188, 189, 190, 191, 192, 204, 215, 217, 219, 222, 227, 229, 230, 231, 233, 234, 236, 252, 260, 262, 267, 272, and/or 279.

### Claim 3 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said peptide hormone species is selected from the group of sequences comprising SEQ ID NOs: 6, 7, 21, 22, 23, 24, 72, 74, 92, 95, 97, 99, 106, 107, 108, 116, 117, 118, 147, 163, 167, 185, 186, and/or 188.

### Claim 4 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said peptide hormone species is selected from the group of sequences comprising SEQ ID NOs: 72, 95, 97, 106, 108, 147, 185, and/or 188.

### Claim 5 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said peptide hormone species is SEQ ID NO: 147.

### Claim 6 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said predetermined specific site of said peptide hormone is within the receptor-binding region.

### Claim 7 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said peptide hormone exhibiting an specific glycosylation pattern of one or more O-linked glycan(s) at a predetermined specific site of said peptide hormone is obtainable by recombinant production using a host cell in which one or more glycosyltransferase gene(s) is/are inactivated or downregulated by inactivation and/or downregulation of one or more gene(s) selected from COSMC and C1GALT1; and/or by inactivation and/or downregulation of one or more gene(s) selected from GCNT3, GCNT4, B3GNT6, and/or by inactivation and/or downregulation and/or upregulation/activation of one or more gene(s) selected from ST6GALNAC1-6, ST3GAL1, GCNT3, GCNT4, and/or B3GNT6.

### Claim 8 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein said peptide hormone species exhibits a specific glycosylation pattern of one or more O-linked glycan(s) at a predetermined specific site of said peptide hormone and, wherein the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with optional elongation and sialic acid capping, wherein optionally the first monosaccharide attached in the synthesis of O-linked glycans is N-acetyl-galactosamine and wherein a core1 structure may be obtained by the addition of galactose, and wherein a core2 structure may be obtained by the addition of N-acetyl-glucosamine to the N-acetyl-galactosamine of the core1 structure and wherein the core3 structures may be obtained by the addition of a single N-acetyl-glucosamine to the first monosaccharide N-acetyl-galactosamin and core4 structures may be obtained by the addition of a second N-acetyl-glucosamine to the core3 structure.

### Claim 9 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein the one or more O-glycan structures include a Tn (GalNAc) structure.

### Claim 10 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6).

### Claim 11 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6).

### Claim 12 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according to claim 1, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3)

### Claim 13 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species according claim 1, wherein the one or more O-glycan structures include the core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6).

### Claim 14 (depends on 1)

A formulation according to claim 1, wherein said formulation is a pharmaceutical formulation.

### Claim 15 (depends on 1)

A formulation comprising at least one molecule of a peptide hormone species as defined in claim 1, wherein said peptide hormone species comprises one or more O-linked glycan at a site indicated in and one of Tables 6A to 6E, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone.

### Claim 16 (depends on 15)

A formulation comprising at least one molecule of a peptide hormone species as defined in claim 15, wherein said peptide hormone species comprises one or more O-linked glycan at a site indicated in Table 6A, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone.

### Claim 17 (depends on 15)

A formulation comprising at least one molecule of a peptide hormone species as defined in claim 15, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6B, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone.

### Claim 18 (depends on 15)

A formulation comprising at least one molecule of a peptide hormone species as defined in claim 15, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6C, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone.

### Claim 19 (depends on 15)

A formulation comprising at least one molecule of a peptide hormone species as defined in claim 15, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6C, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone.

### Claim 20 (depends on 15)

A formulation comprising at least one molecule of a peptide hormone species as defined in claim 15, wherein said peptide hormone species comprises one or more O-linked glycan at a site of a peptide hormone indicated in Table 6D, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone.

### Claim 21

A modified peptide hormone comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6A, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is selected from the group comprising SEQ ID Nos: 1, 2, 3, 5, 6, 7, 14, 15, 16, 21, 22, 23, 24, 25, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 51, 52, 54, 55, 56, 57, 72, 73, 74, 76, 79, 8, 81, 83, 84, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 106, 107, 108, 109, 113, 116, 117, 118, 119, 120, 130, 131, 135, 136, 143, 144, 147, 163, 164, 167, 168, 170, 184, 185, 186, 188, 189, 190, 191, 192, 204, 215, 217, 219, 222, 227, 229, 230, 231, 233, 234, 236, 252, 260, 262, 267, 272, and/or 279.

### Claim 22

The modified peptide hormone comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6B, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is selected from the group comprising SEQ ID Nos: 6, 7, 21, 22, 23, 24, 72, 74, 92, 95, 97, 99, 106, 107, 108, 116, 117, 118, 147, 163, 167, 185, 186, and/or 188.

### Claim 23

The modified peptide hormone comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6C, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is selected from the group comprising SEQ ID Nos: 72, 95, 97, 106, 108, 147, 185, and/or 188.

### Claim 24

The modified peptide hormone comprising one or more O-linked glycan at a predetermined specific site selected from the group comprising the peptide hormones indicated in 6D, particularly, wherein the site is a site in a human peptide hormone, more particularly, wherein the site is a conserved site in a human peptide hormone, and wherein said peptide hormone is depicted in SEQ ID NO: 147.

### Claim 25 (depends on 21)

The modified peptide hormone according to claim 21, wherein the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with sialic acid capping, wherein the one or more O-glycan structures include a glycan structure selected from a core1, core2, core3, or core4 structure with optional elongation and sialic acid capping, wherein optionally the first monosaccharide attached in the synthesis of O-linked glycans is N-acetyl-galactosamine and wherein a core1 structure may be obtained by the addition of galactose, and wherein a core2 structure may be obtained by the addition of N-acetyl-glucosamine to the N-acetyl-galactosamine of the core1 structure and wherein the core3 structures may be obtained by the addition of a single N-acetyl-glucosamine to the first monosaccharide N-acetyl-galactosamin and core4 structures may be obtained by the addition of a second N-acetyl-glucosamine to the core3 structure.

### Claim 26 (depends on 21)

The modified peptide hormone according to claim 21, wherein the one or more O-glycan structures include a Tn (GalNAc) structure.

### Claim 27 (depends on 21)

The modified peptide hormone according to claim 21, wherein the one or more O-glycan structures include Tn (GalNAc) structure with one sialic acid capping (alpha2-6).

### Claim 28 (depends on 21)

The modified peptide hormone according to claim 21, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha2-6).

### Claim 29 (depends on 21)

The modified peptide hormone according to claim 21, wherein the one or more O-glycan structures include the core1 structures with one sialic acid capping (alpha 2-3)

### Claim 30 (depends on 21)

The modified peptide hormone according to claim 21, wherein the one or more O-glycan structures include the core1 structures with two sialic acids capping (alpha 2-3 and alpha 2-6).
